WhitepaperSustainability

Data-Driven ESG Evaluation of Chinese Pharmaceutical and Biotechnology Firms

Sinopep-Allsino ranks in the top 5 of 57 Chinese pharmaceutical and biotechnology firms in a 2026 data-driven ESG evaluation that used machine learning to select indicators and rank companies without expert-assigned weights.

Compare ESG ranking of all companies

Sinopep-Allsino ranks in the top 5 of 57 Chinese pharma and biotech firms in a new data-driven ESG evaluation.

A 2026 open-access study in Big Data and Cognitive Computing (Wang et al.) applied a fully machine-learning pipeline to 2024 ESG data from 57 listed Chinese pharmaceutical and biotechnology companies. Existing commercial ESG ratings frequently diverge because of subjective weighting and incomplete data treatment. Wang and colleagues set out to reduce that subjectivity with an end-to-end, data-driven approach that does not rely on expert-assigned weights at any stage.

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. placed in the top five under the primary ranking and remained in the top five under three of the four weighting schemes tested.

Compare ESG ranking of all companies to Sinopep

Figure 1. Top-ranked Chinese pharmaceutical and biotechnology firms in the primary hybrid PCA-CRITIC + TOPSIS ESG ranking of Wang et al. Jiangsu Sinopep-Allsino is highlighted. Normalized scores are relative to the top firm (BeOne Medicines = 100). Exact scores for all 57 companies appear in the Supplementary Materials.

How the ranking was built

The framework has three modules. First, missing values were imputed with MissForest, a random-forest-based method that iteratively predicts missing entries from the observed data. Second, a three-plane feature-selection process—combining unsupervised clustering, feature-importance ranking, and supervised validation with SHAP (SHapley Additive exPlanations)—reduced 70 available indicators to a balanced set of 15 (five environmental, five social, five governance). SHAP values quantify how much each indicator contributes to distinguishing one firm from another. Third, those 15 indicators were weighted using a hybrid PCA-CRITIC method. PCA (principal component analysis) measures how much of the total variance each indicator explains; CRITIC (Criteria Importance Through Intercriteria Correlation) measures how much distinct information an indicator carries relative to the others. The hybrid weight for each indicator is proportional to the product of its PCA and CRITIC scores. Companies were then ranked with TOPSIS (Technique for Order of Preference by Similarity to Ideal Solution), which scores each firm by its distance from a best-case and worst-case profile. No expert-assigned weights enter the process.Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. placed in the top five under the primary ranking and remained in the top five under three of the four weighting schemes tested.

What set Sinopep apart from most CDMO peers

Most manufacturing-focused companies in the sample showed moderate or low R&D intensity and more typical environmental metrics. Sinopep-Allsino’s 2024 profile combined high R&D investment with relatively low environmental intensity. On the social side, R&D expense growth of 82.12% was among the highest recorded in the 57-company set, and R&D spending equal to 14% of revenue was high for a CDMO. On governance, four board members held PhDs, placing the company in the upper tier on that indicator. On the environmental side, electricity consumption per unit of revenue (28.42), Scope 3 GHG intensity (38.51), and environmental protection tax (0.91) were all low relative to peers, indicating more efficient resource use than most manufacturing-focused firms. These strengths were sufficient to keep Sinopep in the top tier even though female board representation was 0% (the highest-weighted single indicator in the hybrid scheme).

Indicator Sinopep value Relative standing
R&D expense growth % 82.12% Among the highest
R&D expense % of revenue 14.00% High
Board members with PhDs 4 High
Electricity per revenue 28.42 Low (favorable)
Scope 3 GHG intensity 38.51 Low (favorable)
Environmental tax 0.91 Very low (favorable)
Female board % 0% Lowest possible

Table 1. Selected 2024 ESG indicator values for Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. from Table S1 of the Supplementary Materials of Wang et al. Relative standing is assessed against the 57-company Chinese pharmaceutical and biotechnology sample under the framework’s direction (higher or lower treated as more favorable).

These strengths were sufficient to keep Sinopep in the top tier even though female board representation was 0% (the highest-weighted single indicator in the hybrid scheme).

What the ranking does and does not claim

The result is specific to the 15 indicators selected by the authors’ pipeline and to the 57-company Chinese pharmaceutical and biotechnology sample. It is not a commercial ESG rating from MSCI, LSEG, or Sustainalytics, and it does not measure product quality, regulatory inspection history, or other dimensions outside the selected metrics.
Full indicator definitions, company-level data from the Supplementary Materials, and the complete ranking are available in the knowledge-center white paper.

Rank Company Score Rank Company Score Rank Company Score
1 BeOne Medicines 100.0 20 Pharmablock 74.0 39 Assure Tech 64.5
2 WuXi AppTec 93.5 21 Zhejiang Gongdong 73.5 40 Asymchem 64.0
3 Sichuan Biokin 91.0 22 Andon 73.0 41 Hybio 63.5
4 Inner Mongolia Furui 88.5 23 PharmaResources 72.5 42 HitGen 63.0
5 Jiangsu Sinopep-Allsino 86.5 24 BMC 72.0 43 Chison 62.5
6 Acrobiosystems 83.5 25 Porton 71.5 44 Chempartner 62.0
7 Intco 82.5 26 Hangzhou AGS 71.0 45 Shenzhen Glory 61.5
8 Aurisco 81.5 27 Aidite 70.5 46 Guangdong Transtek 61.0
9 Zhonghong Pulin 80.5 28 Shenzhen Hepalink 70.0 47 Mehow Innovative 60.5
10 Zhejiang Haisen 79.5 29 Sino Biological 69.5 48 Nanjing King-Friend 60.0
11 Jenkem 79.0 30 Zhejiang Jiuzhou 69.0 49 Qianjiang Yongan 59.5
12 Zhejiang Ausun 78.5 31 Shantou Ultrasonic 68.5 50 Hangzhou Biotest 59.0
13 Pharmaron 78.0 32 Caina 68.0 51 Honsun 58.5
14 Allmed 77.5 33 Zhejiang Hisoar 67.5 52 Edan 58.0
15 Ningbo Menovo 76.5 34 Contec 67.0 53 Huizhou Jinghao 57.5
16 Kingchem 76.0 35 Guangzhou Jet Bio-Filtration 66.5 54 Jiangxi Synergy 57.0
17 Zhejiang Orient Gene 75.5 36 Bide 66.0 55 Anhui Hongyu Wuzhou 56.5
18 Zhende 75.0 37 Jianerkang 65.5 56 Hangzhou AllTest 56.0
19 Zhejiang Tianyu 74.5 38 Well Lead 65.0 57 Blue Sail 55.5

Table 2. ESG ranking of 57 Chinese pharmaceutical and biotechnology companies (2024). Scores are based on a composite assessment across environmental, social, and governance indicators. Jiangsu Sinopep-Allsino ranks 5th with a score of 86.5.

Rank Company Score
1 BeOne Medicines 100.0
2 WuXi AppTec 93.5
3 Sichuan Biokin 91.0
4 Inner Mongolia Furui 88.5
5 Jiangsu Sinopep-Allsino 86.5
6 Acrobiosystems 83.5
7 Intco 82.5
8 Aurisco 81.5
9 Zhonghong Pulin 80.5
10 Zhejiang Haisen 79.5
11 Jenkem 79.0
12 Zhejiang Ausun 78.5
13 Pharmaron 78.0
14 Allmed 77.5
15 Ningbo Menovo 76.5
16 Kingchem 76.0
17 Zhejiang Orient Gene 75.5
18 Zhende 75.0
19 Zhejiang Tianyu 74.5
20 Pharmablock 74.0
21 Zhejiang Gongdong 73.5
22 Andon 73.0
23 PharmaResources 72.5
24 BMC 72.0
25 Porton 71.5
26 Hangzhou AGS 71.0
27 Aidite 70.5
28 Shenzhen Hepalink 70.0
29 Sino Biological 69.5
30 Zhejiang Jiuzhou 69.0
31 Shantou Ultrasonic 68.5
32 Caina 68.0
33 Zhejiang Hisoar 67.5
34 Contec 67.0
35 Guangzhou Jet Bio-Filtration 66.5
36 Bide 66.0
37 Jianerkang 65.5
38 Well Lead 65.0
39 Assure Tech 64.5
40 Asymchem 64.0
41 Hybio 63.5
42 HitGen 63.0
43 Chison 62.5
44 Chempartner 62.0
45 Shenzhen Glory 61.5
46 Guangdong Transtek 61.0
47 Mehow Innovative 60.5
48 Nanjing King-Friend 60.0
49 Qianjiang Yongan 59.5
50 Hangzhou Biotest 59.0
51 Honsun 58.5
52 Edan 58.0
53 Huizhou Jinghao 57.5
54 Jiangxi Synergy 57.0
55 Anhui Hongyu Wuzhou 56.5
56 Hangzhou AllTest 56.0
57 Blue Sail 55.5

Table 2. ESG ranking of 57 Chinese pharmaceutical and biotechnology companies (2024). Scores are based on a composite assessment across environmental, social, and governance indicators. Jiangsu Sinopep-Allsino ranks 5th with a score of 86.5.

Read the full article:

Wang, Z.; Lim, T.; Teng, Y.; Xia, C. A Data-Driven Machine Learning Framework for Multi-Criteria ESG Evaluation. Big Data Cogn. Comput. 2026, 10, 130. https://doi.org/10.3390/bdcc10050130

The complete study, including methods, robustness checks, and Supplementary Materials with company-level data, is available open access: https://www.mdpi.com/2504-2289/10/5/130

WhitepaperSustainability

Data-Driven ESG Evaluation of Chinese Pharmaceutical and Biotechnology Firms

Sinopep-Allsino ranks in the top 5 of 57 Chinese pharmaceutical and biotechnology firms in a 2026 data-driven ESG evaluation that used machine learning to select indicators and rank companies without expert-assigned weights.

Compare ESG ranking of all companies

Download White Paper

Enter your details to download the PDF of the complete white paper. 

Name(Required)
This field is hidden when viewing the form

We respect your privacy. We will not share your information with any third parties.

Related Articles

Quality by Design for an Oral Semaglutide Tablet

Quality by Design for an Oral Semaglutide Tablet

Yoon J-H, Kim D-H, Kim J-E. Quality by Design-Based Formulation Development of an Oral Semaglutide Tablet. Pharmaceutics. 2026;18:440. https://doi.org/10.3390/pharmaceutics18040440 Oral GLP-1 analogues still have to clear enzymatic degradation, a pH-dependent solubility shift, and poor epithelial...

read more
Efficient Hybrid Synthesis of Amycretin

Efficient Hybrid Synthesis of Amycretin

Multi-receptor agonist peptides are one of the fastest-growing areas in metabolic disease. Molecules such as Novo Nordisk’s amycretin, a dual GLP-1 and amylin receptor agonist, combine two full-length bioactive sequences, a non-natural N-terminal residue, and a C-terminal primary amide in a single...

read more